Publications by authors named "Michael Daunov"
Article Synopsis
- Novel therapies like CAR-T, BTK inhibitors, and PD-1 inhibitors have transformed the treatment of aggressive B-cell lymphomas but can also lead to late side effects like second cancers and treatment failures.
- CAR-T therapy is now preferred over autologous transplant for recurrent diffuse large B-cell lymphoma, while autologous transplant remains important for certain relapses and CNS lymphoma consolidation.
- Allogeneic stem cell transplants are generally reserved for cases where autologous transplants fail, offering lower relapse rates but higher complications, highlighting the need for careful patient selection and treatment timing.
Functional blockade of the transforming growth factor-beta (TGFβ) signalling pathway improves the efficacy of cytotoxic and immunotherapies. Here, we conducted a phase 1b study (ClinicalTrials.gov.
View Article and Find Full Text PDFObjective: This study aimed to determine if treatment with IVIG of neonates with ABO incompatibility (without Rh incompatibility) results in decreased number of packed red blood cell (pRBC) transfusions and phototherapy use.
Study Design: An Institutional Review Board (IRB)-approved, single-institution retrospective study was conducted. Neonates ≥38 weeks' gestational age born between January 1, 2007, and December 31, 2016, with ABO incompatibility were included.
Functional blockade of the transforming growth factor-beta (TGF-β) signaling pathway improves the efficacy of cytotoxic and immunotherapies. We conducted a phase 1b study to determine the safety, efficacy, and maximal tolerated dose (200 mg po bid) of the potent, orally-available TGF-β type I receptor kinase inhibitor vactosertib in relapsed and/or refractory multiple myeloma patients who had received ≥2 lines of chemoimmunotherapy. Vactosertib combined with pomalidomide was well-tolerated at all doses, had a manageable adverse event profile and induced durable responses with 80% progression-free survival (PFS-6) at 6 months, while pomalidomide alone historically achieved 20% PFS-6.
View Article and Find Full Text PDFBackground: This study sought to evaluate the current services and delivery models of adolescent and young adult oncology (AYAO)-specific programs at NCI-designated Cancer Centers (NCI-CCs).
Patients And Methods: NCI, academic, and community cancer centers were electronically sent surveys from October to December 2020 and administered via REDCap.
Results: Survey responses were received from 50 of 64 (78%) NCI-CCs, primarily completed by pediatric oncologists (53%), adult oncologists (11%), and social workers (11%).